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a b s t r a c t
Background: S-nitrosylation of mitochondrial enzymes involved in energy transfer under nitrosative stress may
result in ATP deﬁciency. We investigated whether α-lipoic acid, a powerful antioxidant, could alleviate
nitrosative stress by regulating S-nitrosylation, which could result in retaining the mitochondrial enzyme activity.
Methods: In this study, we have identiﬁed the S-nitrosylated forms of subunit 1 of dihydrolipoyllysine
succinyltransferase (complex III), and subunit 2 of the α-ketoglutarate dehydrogenase complex by implementing
a ﬂuorescence-based differential quantitative proteomics method.
Results: We found that the activities of these two mitochondrial enzymes were partially but reversibly inhibited
by S-nitrosylation in cultured endothelial cells, and that their activities were partially restored by supplementation of α-lipoic acid. We show that protein S-nitrosylation affects the activity of mitochondrial enzymes that are
central to energy supply, and that α-lipoic acid protects mitochondrial enzymes by altering S-nitrosylation levels.
Conclusions: Inhibiting protein S-nitrosylation with α-lipoic acid seems to be a protective mechanism against
nitrosative stress.
General signiﬁcance: Identiﬁcation and characterization of these new protein targets should contribute to
expanding the therapeutic power of α-lipoic acid and to a better understanding of the underlying antioxidant
mechanisms.
© 2015 Elsevier B.V. All rights reserved.

1. Introduction
Nitric oxide (NO) is a soluble and highly diffusible gas generated by a
wide variety of cell types including vascular endothelial cells. NO plays
an important role in endothelium-derived smooth muscle relaxation
[1]. Excess production of endogenous NO under inﬂammatory conditions can be toxic to vascular endothelial cells [2]. Unregulated NO
production leads to an increase in Reactive Nitrogen Species (RNS)
resulting in nitrosative stress (NS), which may give rise to signiﬁcant
pathological outcomes including cellular injury and disease [3]. Speciﬁcally, NS is involved in the pathogenesis of low-grade chronic
inﬂammatory-associated diseases such as atherosclerosis and type 2
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diabetes [4,5]. A better understanding of NS-associated underlying mechanisms may help improve therapeutic outcomes for these diseases.
Evidence shows that NO regulates protein function via S-nitrosylation,
a reversible redox post-translational modiﬁcation that adds an NO group
to a reactive cysteine residue in regulatory proteins [6]. In recent years,
protein S-nitrosylation has received much attention as an ubiquitous regulatory strategy for multiple biological processes [7,8,9]. NO-induced protein S-nitrosylation results in the modulation of active-site thiol and
disulﬁde formation that could either inhibit or enhance the catalytic activity of redox-sensitive enzymes [10]. Some investigations have suggested
that S-nitrosylation is involved in both normal and abnormal vascular
function [6], including regulation of key metabolic pathways [11].
Endothelial cells form the inner cellular lining of blood vessels and
play a key role in regulating vascular cellular homeostasis, vascular
integrity, vasorelaxation, and local inﬂammation [12]. Dysfunction of
the endothelium may result in pathogenic processes associated with a
number of cardiovascular diseases such as atherosclerosis, hypertension,
heart attack and stroke [13]. Because the endothelium constitutively expresses endothelial nitric oxide synthase (eNOS) and is exposed to NO
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derived from the inducible nitric oxide synthase (iNOS) isoform under inﬂammatory conditions [14]. NO increase has been found to coincide with
an increase in protein S-nitrosylation, so it is an ideal tissue for studying Snitrosylation-dependent signals [15]. It is thought that the endogenous
production of NO in the endothelium is not sufﬁcient to inhibit endothelial cell activation during inﬂammation, and that higher concentrations of
NO derived from the use of an exogenous NO donor, DETA-NONOate, is
required for inducing higher levels of protein S-nitrosylation [16].
α-Lipoic acid (1,2-dithiolane-3-pentanoic acid; LA) is a di-thiol
antioxidant with diverse functions such as RNS quenching, antiinﬂammatory activity [17], and may be therapeutic in mitochondriarelated disorders [18,19]. LA is also a cofactor for several enzymes
including pyruvate dehydrogenase complex (PDC) and α-ketoglutarate
dehydrogenase complex (KDC), two mitochondrial enzymes involved
in glucose metabolism and energy production. In a previous study, we
reported that endogenous LA production is necessary for mouse embryo
survival [20]. This result led us to propose that in addition to its antioxidant capacity, LA is essential for the maintenance of normal levels
of energy metabolism [20]. We also found that LA increased the mitochondrial antioxidant capacity, and partially restored mitochondrial
enzyme activity and increased ATP yield during sepsis in which an
excess of NO had been produced [21]. Other investigators have also
reported that the exposure of endothelial cells to small molecular
S-nitrosothiols signiﬁcantly down-regulates their mitochondrial function [22]. Therefore, we hypothesized that inﬂammation-induced excess
NO production increases protein S-nitrosylation, which may result in
diminished oxidative phosphorylation and decreased energy production
in some mitochondrial enzymes. We propose that LA is able to alleviate
mitochondrial dysfunction by regulating protein S-nitrosylation, thus
helping cells to retain their energy supply. In this study, we found that
through alteration of protein S-nitrosylation, LA partially restores
mitochondrial oxidative phosphorylation reserve capacity and ATP
production. These ﬁndings shed light on a novel mechanism by which
LA is able to rescue energy deﬁciency in inﬂammation-associated
diseases, including low-grade chronic inﬂammation diseases, such as
atherosclerosis and type 2 diabetes.
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cells and the cell line. The primary cells and the brain cells were cultured
in Complete Mouse Endothelial Cell Medium (Cell Biologics), and in
Dulbecco's Modiﬁed Eagle Medium (DMEM) containing 10% fetal
bovine serum (Gibco, Langley, OK), respectively. Both cell types were
maintained in a humidiﬁed incubator gassed with 5% CO2, 95% air at
37 °C. LA was dissolved in 100 mM phosphate buffer (pH 7.2) after
being converted into LA sodium salt. A concentration of 50 μM of LA
shows effective protection against oxidative stress in cell cultures
[23–25]. Preparation of DETA-NONOate was based on the method by
Dranka et al. [26], in which an appropriate dose to induce NS in endothelial cells (~ 250 μM) was established. The amount of NO from
DETA-NONOate was released at a constant rate (~150 nM/min) during
the ﬁrst 8 h, and was monitored by absorbance spectroscopy. This
concentration of DETA-NONOate is capable of decreasing the oxygen
consumption rate (OCR) [26]. Therefore, this is the concentration that
we used for cell treatments in this study. Cell counting was performed
using a Neubauer chamber, and the number of dead cells was determined by trypan-blue exclusion before and after treatment. The analysis
was performed with 4 groups, 5 samples per group, which were created
as follows from cell cultures grown to ~ 60% conﬂuence: group 1:
untreated cells (control group); group 2: cells in regular medium for
6 h followed by treatment with LA for 12 h (LA group); group 3: cells
treated with DETA-NONOate for 6 h from time zero and then changed
to fresh medium for 12 h (NO group); and group 4: cells treated with
DETA-NONOate for 6 h, followed by a change to an LA-containing
medium for 12 h (NO + LA group).
2.3. Mitochondrial isolation and purity examination

(Z)-1-[2-(2-aminoethyl)-N-(2-ammonioethyl) amino] diazen-1ium-1,2-diolate (DETA-NONOate) was obtained from Cayman Chemical
(Ann Arbor, MI). Protease inhibitor cocktail (Complete™ Mini EDTAfree protease inhibitor cocktail) was from Roche Applied Science
(Indianapolis, IN). Antimycin A, coenzyme A, cytochrome C, ferricytochrome C, carbonylcyanide p-triﬂouromethoxyphenyl-hydrazone
(FCCP), oligomycin, potassium cyanide, S-methyl methanethiosulfonate
(MMTS), rotenone, thiamine pyrophosphate, urea, CHAPS, neocuproine
and cuprizone were all from Sigma-Aldrich (St. Louis, MO).
Decylubiquinol was from Santa Cruz Biotechnology, Inc. (Dallas, TX);
and R(+) α-lipoic acid (LA) was from Toronto Chemical Research
(Toronto, Canada). NHS-Cy dyes and dye maleimides were from GE
Healthcare (Piscataway, NJ).

Mitochondria were isolated from aortic endothelial cells using a
Mitochondria Isolation Kit for cultured cells, the reagent-based method
(Thermo Fisher Scientiﬁc, Rockford, IL, Product No. 89874) following
the manufacturer's instructions. Certain critical points of puriﬁcation
procedure provided by other optimized protocols were applicable to
our puriﬁcation [27,28]. Harvested cells were homogenized in ice-cold
isolation buffer (100 mM Tris–MOPS, 10 mM EGTA/Tris, 200 mM
sucrose, pH 7.4). The homogenate was centrifuged for 10 min at
3000 × g at 4 °C. The supernatants were collected in isolation buffer,
and then centrifuged for 10 min at 10,000 × g at 4 °C. The resulting
pellets were re-suspended in ~ 1 mL isolation buffer, kept on ice and
used within 4 h or stored at −80 °C for later use.
The purity of the isolated mitochondria compared to cytosolic
fractions was assessed via Western blot analysis for HSP60 or Tubulin
and quantitated using Image Studio Light software (LICOR Biotechnologies, Lincoln, Nebraska). Protein concentrations were measured using
the Thermo Scientiﬁc™ BCA Protein Assay Kit (Product No. 23,225). A
total of 20 μg of cytosolic proteins and 18.8 μg of mitochondrial proteins
(the different loading amounts were normalized during quantitative
calculation afterwards) were loaded on 12% kD™ Mini-PROTEAN®
TGX™ Precast gels (BioRad, Hercules, CA) and transferred onto nitrocellulose membranes. Membranes were blocked with 4% BSA for 1 h.
Proteins were detected with anti-HSP60 (Rabbit polyclonal, 1:10,000,
Abcam Cat# AB46798) and anti-tubulin (Mouse monoclonal antitubulin, beta III isoform, Chemicon Cat# MAB 1637), followed by
secondary horseradish peroxidase (HRP)-conjugated antibody, either
rabbit IgG (1:500) or mouse IgG (1:500), from Jackson ImmunoResearch
Laboratories, Inc. (West Grove, PA). Signals were detected with a chemiluminescence detection kit (Millipore).

2.2. Cell cultures

2.4. Determination of mitochondrial levels of antioxidant and oxidative stress

Primary aortic endothelial cells from C57BL/6J mice (Cell Biologics,
Chicago, IL) and mouse brain endothelioma cells (bEnd.3, American
Type Culture Collection, Manassas, VA) were used in these studies.
The latter, an alternative source of endothelial cells, was used to
compare the possible different responses to NS between the primary

Isolated mitochondria prepared as described above were deproteinated
with 5% trichloroacetic acid. The level of reduced glutathione (GSH), a
major endogenous antioxidant in mitochondria, was determined with a
Glutathione Assay Kit from Cayman Chemical. The protein concentration
of each sample was determined using a bicinchoninic acid assay (BCA;

2. Materials and methods
All animal protocols were reviewed and approved by the Ethics
Committee of the University of North Carolina at Chapel Hill (Protocol
number: 13-208-0).
2.1. Reagents
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Thermo Fisher Scientiﬁc). Mitochondrion oxidative stress was measured
using 4-Hydroxynonenal (4-HNE) assay kit in accordance with
manufacturer's speciﬁcations (Cell Biolabs, Inc. San Diego, CA).
Mitochondrial nitrate/nitrite (NOx) levels, as the stable metabolic end
products of NO, were determined using a colorimetric assay kit (Cayman
Chemical). The absorbance was read on a Biotek Synergy HT Multi-Mode
microplate reader (Winooski, VT, USA) using a wavelength of 540 nm. Protein carbonyl content was assessed by using an OxiSelect Protein Carbonyl
ELISA kit according to the manufacturer's instructions (Cell Biolabs, Inc.).
2.5. Determination of ATP production
ATP generation in the DETA-NONOate-treated primary aortic endothelial cells was analyzed by a luciferase substrate assay (Invitrogen,
Carlsbad, CA). Brieﬂy, the cells were homogenized and sonicated in
ATP Assay Buffer provided by the company. After centrifugation at
12,000 × g for 5 min at 4 °C, the supernatant was removed and used
for ATP measurement in an Orion Microplate Luminometer (Berthold
Detection Systems, Titertek Instruments, Inc., Huntsville, AL). The
amount of ATP was normalized to the protein concentration as determined by the BCA method.
2.6. Measurement of the oxygen consumption rate (OCR) and the extracellular acidiﬁcation rate (ECAR)
OCR and ECAR were measured using the XF24 extracellular ﬂux
analyzer (Seahorse Bioscience, Billerica, MA) following the manufacturers' instructions. Brieﬂy, primary aortic endothelial cells were seeded
at a density of 5 × 104 cells per well, treated with 250 μM DETANONOate, followed by 50 μM LA. The cells were washed with PBS
and incubated with bicarbonate-free (no buffering capacity) DMEM at
37 °C for 1 h. Measurements were taken sequentially, as the cells were
incubated, with the following chemicals: (1) oligomycin (5 μg/mL), a

reversible inhibitor of ATP synthase; (2) FCCP (5 μM), an electron
uncoupler of ATP synthesis; and (3) antimycin A (40 μM), a complex
III inhibitor. Basal levels of OCR and ECAR were obtained in the cultured
cells without the additives.
2.7. Proteomic analysis
Conﬂuent cells were washed four times with cold PBS, re-suspended
in 500 μL of cold PBS supplemented with Complete™ protease inhibitor
cocktail without EDTA, and spun at 2000 ×g for 20 min at 4 °C. Pelleted
cells were re-suspended in 500 μL lysis buffer (8 M urea, 4% CHAPS,
30 mM Tris, pH 8.5) supplemented with protease inhibitor cocktail,
and then sonicated on ice three times, for 20 s each with 10 s rest.
After centrifugation, the resulting supernatants were cleaned up using
a 2D Clean-Up kit (GE Healthcare), according to the manufacturer's
instructions. The ﬁnal pellet was re-suspended either in lysis buffer or
S-nitrosylated-labeling buffer (8 M urea, 4% CHAPS, 20 mM Tris,
pH 7.3) and the protein concentration was determined using a 2D
Quant kit (GE Healthcare) as instructed by the manufacturer.
A modiﬁed ﬂuorescence-switch method [29] was used to detect
S-nitrosylated proteins as follows. Protein samples were re-suspended
in S-nitrosylation-labeling buffer, MMTS was added to 100 μg of protein
sample to produce a ﬁnal concentration of 20 mM MMTS, and then
incubated at room temperature for 1 h while being protected from
light. The samples were cleaned up as previously described [30] to
remove unbound MMTS. Then the samples were re-suspended in
S-nitrosylation-labeling buffer, and ﬁnally ascorbic acid was added to a
ﬁnal concentration of 100 mM (Fig. 1). Samples were cleaned again
and the resulting pellets were re-suspended in S-nitrosylation-labeling
buffer, followed by the addition of 500 pmol of Cy5-maleimide and
ﬂushed with nitrogen to decrease the possibility of protein oxidation.
Samples were incubated at room temperature for 2 h followed by
incubation overnight at 4 °C, protected from light.

Fig. 1. Experimental design. Protein preparations from four samples were used for SNO analysis: untreated samples used as the Control group; samples from cells treated with nitric oxide
(NO group); samples from cells treated with LA (LA group); and samples from cells that were treated with NO, followed by treatment with LA (NO + LA). Each group was divided into
three fractions: fraction one consisted of 20 μL from each sample, these samples were pooled, and labeled with NHS-Cy2 to develop an internal control (IC). This IC was used for image
normalization, and differential expression analysis; fraction two, consisted of 100 μg of total protein sample that was treated ﬁrst with MMTS to block free sulfhydryl groups, then treated
with ascorbate to remove the NO groups, and then labeled with Cy5-maleimide, to label the free –SH groups that resulted from the ascorbate treatment. This fraction provides a red color
when scanned with the Typhoon TRIO+; and fraction three (SHAM) consisting of 100 μg of sample and treated as fraction two, without adding MMTS, or ascorbate. This fraction was
labeled with NHS-Cy3, and used to determine the total amount of protein. In principle, it is expected that every protein that was initially nitrosylated would provide a ﬂuorescent red
color after the treatment. After sample treatment and labeling, the proteins were fractionated by 2D Fluorescent gel electrophoresis. The differences in total protein expression, and protein
nitrosylation were determined with the Decyder 2D software {DeKroon et al., 2011—Ref. 29}.
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An internal control (IC) was prepared by pooling equal amounts
of protein (20 μg) from all control samples, which were labeled with
400 pmol/50 μg protein of NHS-Cy2. Aliquots from the IC were added to
each gel. A 100 μg aliquot of each sample was processed as the
S-nitrosylation sample without adding either MMTS or ascorbate. After
clean-up, these samples were labeled with 400 pmol of NHS-Cy3 to determine total protein expression changes. The labeling reactions were carried out on ice for 30 min, protected from light. To quench the reaction,
1 μL of 10 mM lysine was added, and the reaction was incubated for an additional 10 min on ice in the dark. After labeling, corresponding samples
were combined as shown in Fig. 1. An equal volume of 2× sample buffer
(8 M urea, 4% CHAPS, 20 mg/mL DTT, 2% (v/v) IPG buffer 4–7 (GE
Healthcare)) was added and the mixture was placed on ice for 15 min. Rehydration buffer (8 M urea, 4% CHAPS, 2 mg/mL DTT, 1% (v/v) IPG buffer
4–7) was added to a ﬁnal volume of 250 μL.
2.8. Differential ﬂuorescence 2D gel electrophoresis and image analysis
Differential ﬂuorescence 2D gel electrophoresis was carried out as reported previously [31]. After electrophoresis, the gels were scanned with
a Typhoon Trio + (GE Healthcare). Gel images were analyzed as described [31] with Decyder 2D software Ver7.0 (GE Healthcare). The
resulting images for S-nitrosylated proteins and total protein differential
expression were analyzed separately, using the same internal control because the nitrosylated proteins within each group were assigned unique
spot numbers, and the “total” protein spot numbers very often do not correlate to the same protein spot [31] due to the isoelectric point shift
resulting from the different labels. Spot maps for each gel image (individual samples and internal control) were matched and an ANOVA (SAS Institute Inc., Cary, NC) comparison was performed between Control, LA,
NO, and (NO + LA) for each spot. The extended data analysis (EDA) component of DeCyder 7.0 was used for principal component analysis (PCA)
and hierarchical cluster analysis (HCA).
2.9. Protein identiﬁcation by mass spectrometry (MS)
For protein identiﬁcation purposes, approximately 400 μg of total protein consisting of equal contributions from each experimental group was
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separated by 2D gel electrophoresis for spot picking. Matching protein
spots between the pick gel and the analytical gels were picked using an
Ettan spot picker (GE Healthcare), and digested with trypsin as previously
described [32]. Proteins were identiﬁed using a 4800 MALDI TOF/TOF
(Applied Biosystems (AB), Foster City, CA) mass spectrometer either at
the UNC Proteomics Core Facility or the US EPA NHEERL Proteomics Research Core Facility. Mascot software (http://www.matrixscience.com/)
was used to identify the proteins from background-subtracted MALDIMS and MS/MS data. MALDI-MS acquisition was followed by MALDIMS/MS peptide sequencing, and the ﬁnal protein identiﬁcation was obtained using Protein Pilot 3.0 software (AB SCIEX, Framingham, MA),
searching against the mouse (Mus musculus) sub-database of the
SwissProt protein database (http://expasy.org/sprot/). Mass-selected
MALDI-MS/MS spectra acquisition was performed to increase the protein
sequence coverage. The reported proteins were identiﬁed based on at
least two high-quality (95–99% peptide conﬁdence scores in Protein
Pilot) peptide sequence identiﬁcations made from the MS/MS data
[32].
2.10. Alpha-ketoglutarate dehydrogenase (KDC) and complex III activities
in mitochondria
KDC activity in isolated mitochondria was determined by monitoring
the reduction of NAD+ at 340 nm. Brieﬂy, isolated mitochondria were
resuspended in buffer containing 25 mM KH2PO4, 5 mM MgCl2,
0.5 mM EDTA, 0.1% (v/v) Triton X-100, 40 mM rotenone, 1.0 mM
NAD+, 0.2 mM thiamin pyrophosphate, and 0.1 mM Coenzyme A,
pH 7. The mitochondria were sonicated in a water bath at room temperature for 30 s. A reaction mixture containing 5 mM MgCl2, 40 mM
rotenone, 0.1 mM Coenzyme A, 0.2 mM thiamine pyrophosphate and
1 mM NAD+ were added to the mitochondrial medium to reach a
ﬁnal concentration of 0.4 mg mitochondrial protein/mL. The reaction
was initiated by the addition of 2.5 mM α-ketoglutarate [33]. Complex
III (ubiquinol–ferricytochrome C oxidoreductase; EC 1.10.2.2) activity
in mitochondria was measured by following the increase in absorbance
at 550 nm due to the reduction of ferricytochrome C [34]. The reaction
mixture consisted of 25 mM KH2PO4, pH 7.4, 5 mM MgCl2, 2 mM KCN,
2.5 mg bovine serum albumin, 50 μM cytochrome C, and 4 mg rotenone.

Fig. 2. LA increased ATP production and mitochondrial GSH levels. A) ATP production in primary aortic endothelial cells treated with the NO donor, DETA NONOate, in the presence or
absence of LA. Each group was collected from 3 independent experiments. B) Mitochondrial 4-HNE level was increased after NO treatment and that LA-treated cells signiﬁcantly offset
this effect of NO. C) Reduced glutathione (GSH) levels in mitochondria isolated from the NO donor-treated cells with or without LA. D) Total NOx level in mitochondrial fraction was
markedly elevated after treatment with DETA-NONOate whereas LA supplementation signiﬁcantly attenuated the elevated amount of NOx. E) Cellular carbonyl levels increased by 71%
in mitochondria isolated from NO-treated cells as compared to control cells (p b 0.05), whereas addition of LA signiﬁcantly reduced carbonyl formation. Data from ﬁve independent
experiments are expressed as the mean ± SEM.
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Fig. 3. LA restored OCR and ECAR, inhibited by nitrosative stress in endothelial cells. A) Oxygen consumption rates (OCR), B) Extracellular acidiﬁcation rate (ECAR) in the primary aortic
endothelial cells, and C) OCR in brain endothelial cells, were measured using a Seahorse extracellular ﬂux analyzer. The cells were treated with DETA NONOate (ﬁnal concentration
250 μM) for 6 h and then fed LA (50 μM) for 12 h, followed by the sequential addition of oligomycin, FCCP, and antimycin A as shown. Data are shown as means SEM of n = 18 wells
(each group) collected from 3 independent experiments. The OCR and ECAR values are normalized by cell numbers.

Mitochondrial protein (25 μg) was added and the reaction was initiated
by the addition of 60 μM decylubiquinol, and the change in absorbance
was monitored for 2 min. To determine antimycin-insensitive activity,
the assay was repeated by adding 5 μg antimycin A to the reaction
mixture. Antimycin A-sensitive complex III activity was calculated by
comparing the resulting values with the initial rate, which was used
as the base value. Enzyme activity was expressed as nmole of reduced
cytochrome C per minute per mg of protein.

2.11. Statistical analysis
All data are reported as mean ± standard error of the mean
(SEM). Values of p b 0.05 were considered to be statistically signiﬁcant (95% conﬁdence limits). The signiﬁcance of the effects of NO,
LA, NO + LA and non-treated control groups was compared using
one-way ANOVA.

3. Results
3.1. Effect of LA on ATP production, mitochondrial function and redox status
We measured ATP levels in endothelial cells to determine the effect
of excess NO on ATP production. We found that after treatment with
DETA-NONOate ATP production decreased by 36% compared to control
cells and that LA supplementation signiﬁcantly restored ATP levels
(Fig. 2A); it is worth noting that LA alone did not affect ATP levels
(Fig. 2A). We measured 4-HNE and GSH concentrations in the
mitochondria to evaluate whether or not administration of LA alters
oxidative stress and can compensate for possible loss of mitochondrial
antioxidant capacity due to RNS. Our results show that the mitochondrial
4-HNE level increased by 57% whereas GSH decreased by ~40% after NO
treatment (p b 0.01) and that LA-treated cells are less effected by NO.
While LA alone did not signiﬁcantly reduce 4-HNE and increase GSH
levels without DETA-NONOate treatment, it suggests that the major

Fig. 4. Overlaid images of SNO proteins. Changes in protein S-nitrosylation as well as changes in total protein expression were analyzed using a modiﬁcation of the Biotin-switch method.
The whole process was illustrated in Fig. 1, and here we show representative images of 2D gels containing S-nitrosylated and non-nitrosylated proteins, and visual evidence that the
Cy-maleimide labeling of the modiﬁed proteins induces pI shifts. A) NO + LA: Cy2 (blue) is used to labeled LA-treated samples used as control; Cy3 (green) shows proteins treated
with NO + LA; Cy5-M (Red) shows nitrosylated proteins. B) Grayscale of Cy3 (Green), i.e., proteins treated with NO + LA. C) NO + LA: Cy3 (Green) is used to label proteins treated
with NO + LA; Cy5-M (Red) is nitrosylated proteins. D) Grayscale of Cy5 (red), i.e., Nitrosylated proteins. These images demonstrate ‘matching’ between total protein and the internal
control, while Cy5-M produces a shift in isoelectric point as exempliﬁed by the spots in oval.
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Fig. 5. Total numbers and categories of mass spectrometry-identiﬁed A) S-nitrosylated proteins; and B) differentially expressed proteins. C) Principal component analysis (PCA).
(Top panel) PCA for SNO proteins. Principal component 1 (PC1) demonstrates that the addition of LA (LA or NO + LA) was the dominant component effecting protein S-nitrosylation.
The second principle component (PC2) was between NO + LA and all other treatment groups. (Bottom panel) PCA for total protein expression. The addition of LA (LA or NO + LA)
was again the ﬁrst principal component effecting protein expression. PC2 was between NO + LA and all other treatment groups. D) Hierarchical cluster analysis. With both S-nitrosylated
(SNO) and total protein differences LA and NO + LA were clustered together, separate from control and NO which were also clustered together.

effect of LA on 4-HNE and GSH production is mediated through RNS
quenching (Fig. 2B and C). In addition, the total NOx level in mitochondrial fraction was markedly elevated after treatment with DETANONOate. Supplement with LA signiﬁcantly attenuated the elevated
amount of NO (Fig. 2D), reaching basal levels. Likewise, the ELISA results
showed that cellular carbonyl levels increased by 71% in mitochondria
isolated from NO-treated cells as compared to control cells (p b 0.05),
whereas addition of LA signiﬁcantly reduced carbonyl formation
(Fig. 2E). Collectively, these data demonstrate that cells treated with
NO have increased levels of RNS and ROS, which are opposed by LA
supplementation, partially alleviating the stress.
To determine whether the mitochondrial reserve capacity was
altered by excess NO and potentially regulated by LA we examined
OCR and ECAR in primary aortic endothelial cells and in brain endothelial
cells treated with DETA-NONOate with and without LA supplementation. Mitochondrial reserve capacity was determined by uncoupling
oxidative phosphorylation with the proton ionophore FCCP, followed
by the addition of mitochondrial respiratory-chain complex inhibitors.
First, oligomycin (5 μg/mL) was added to all samples to inhibit ATP
synthase (complex V), and then FCCP (5 μM) was added. Exposure of
endothelial cells to FCCP, which uncouples electron ﬂow for ATP synthesis, stimulates respiration to the maximal level and provides an important
indicator of mitochondrial reserve capacity (Fig. 3A). Lastly, antimycin A
(40 μM) was added to inhibit electron ﬂow through complex III, which
causes a dramatic suppression of OCR (Fig. 3A). OCR was signiﬁcantly
decreased in cells exposed to NO (106 ± 11 pmoles/min) compared to
OCR basal levels (182 ± 9 pmoles/min), whereas treatment with LA

signiﬁcantly offset this decline (163 ± 7 pmoles/min; p b 0.001). As
indicated in Fig. 3B, after the addition of FCCP, NO induced a 50% increase
in ECAR compared to control (p b 0.01) while LA lowered ECAR by 22.5%
(p b 0.05). OCR in brain endothelial cells showed comparable values
(Fig. 3C), suggesting that the effect of LA on OCR and ECAR is not exclusive
to primary-cells.
To determine whether or not LA assists retaining mitochondrial
energy production by altering protein S-nitrosylation, we examined
changes in total protein levels and S-nitrosylated proteins by a modiﬁed
2D DIGE-based biotin-switch method, in which both the traditional 2D
DIGE and the biotin-switch approaches were modiﬁed. Each 2D gel
contained aliquots labeled for S-nitrosylation and total protein from a
single sample, and a pooled internal control (Fig. 1). S-nitrosylated
Table 1
S-Nitrosylated proteins that were affected by addition of LA.
Spot no.

Protein identity

Ratio

ANOVA

Matched
peptides

771
880
1097
1104

Heat shock cognate 71 kDa protein
Isoform C of Prelamin-A/C
Protein Prss3
Dihydrolipoyllysine
succinyltransferase of KDC
Cytochrome b-c1 complex subunit I
β-Actin
Prohibitin

−3.0
−1.25
+3.1
−2.0

0.043
0.045
0.008
0.037

8
6
23
24

−2.3
−2.0
−2.2

0.024
0.034
0.046

15
16
12

1292
1494
2031

LA: lipoic acid.
KDC: alpha-ketoglutarate dehydrogenase complex.

42

S. Hiller et al. / Biochimica et Biophysica Acta 1860 (2016) 36–45

Table 2
Proteins that displayed changes in expression affected by LA.
Spot no.

Protein identity

Ratio

ANOVA

Matched
peptides

577
741
1048
1150
1319
1327

Zyxin
Heat shock 70 kDa protein 5
protein disulﬁde-isomerase
Vimentin
Ribonuclease inhibitor isoform a
Cytochrome b-c1 complex subunit I

−2.1
−2.6
+4.6
−3.2
+1.4
+2.0

0.033
0.025
0.039
0.03
0.007
0.026

8
32
21
36
6
15

LA: lipoic acid.

proteins were recognized utilizing Cy5-maleimide (Cy5-M), and changes
in expression levels (total protein) were determined by labeling the
proteins with NHS-Cy3. Since maleimide-labeled proteins often display
shifts in gel migration due to charge changes, an internal protein control,
labeled with NHS-Cy2, was used to normalize total protein expression
and determine changes in migration patterns. As expected from the
Cy5-M labeling, there was an isoelectric point (pI) shift relative to the
same sample labeled for total protein with NHS-Cy3 (Fig. 4, A–D). The
resulting images for S-nitrosylated proteins and total protein changes
were analyzed separately as described previously [29,30].

All the reported results are statistically signiﬁcant as determined by
p b 0.05. Differential expression analysis revealed that 51 S-nitrosylated
proteins presented expression level changes (Fig. 5A), while total
expression levels of 67 of the non S-nitrosylated proteins changed
(Fig. 5B). Fifteen (27%) of the 51 differentially S-nitrosylated proteins
that were affected by NO were subsequently affected by the LA treatment. Of these, two-thirds of the proteins were characterized
as having reduced S-nitrosylation levels resulting from LA treatment
(addition of LA to the cell cultures in the presence of NO; data not
shown). Addition of LA alone affected 26 (51%) of the S-nitrosylated
proteins (Fig. 5A). In contrast, 5 (10%) of the S-nitrosylated proteins
that resulted from the effects of NO were not affected by LA supplementation (Fig. 5A). From the 67 non-S-nitrosylated proteins displaying
altered protein expression levels, 12 proteins (18%) that were affected
by NO were also affected by LA (Fig. 5B); and 37 proteins (56%) were
affected by the LA treatment alone (Fig. 5B). Finally, nine of the proteins
(13%) that were altered by NO, were not affected by LA.
Statistically signiﬁcant observations were further corroborated by
hierarchical cluster analysis and principal component analysis (PCA).
Principal component 1 (PC1) for S-nitrosylated proteins (Fig. 5C, top
panel), which contains 55.5% of the variance between samples,
conﬁrmed that the addition of LA (LA or NO + LA) is the dominant

Fig. 6. Activities of complex III and alpha-ketoglutarate dehydrogenase (KDC) in mitochondria isolated from the nitric oxide donor-treated cells with or without LA. A) Purity of mitochondrial
preparations assessed by Western blot. Ten randomly selected cytosolic (a and c) and mitochondrial (b and d) fractions were immunoblotted with antibodies against β-Tubulin and
HSP60. B) The amounts of the proteins were quantiﬁed by Image Studio Light software. Results are given as band intensities of Western blot signals, represented as mean ± SEM.
C) Complex III activity was expressed as nmole of reduced cytochrome C/min per mg of protein. D) KDC activity was determined by monitoring NAD+ reduction at 340 nm. E and
F) Activities of complex III and KDC were increased after adding Cu+ to the NO-treated group. In the presence of the speciﬁc Cu+ chelator neocuproine (NCP), the effect of Cu+ was
completely abolished. However, adding the Cu++ chelator cuprizone (CPZ), had no effect on the enzyme activities. Data from ﬁve independent experiments are expressed as the
mean ± SEM.
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Fig. 6 (continued).

component affecting protein S-nitrosylation. On the other hand, PC2,
with 24.2% of variance, is between (NO + LA) and all other treatment
groups. For differences in total protein expression, PC1 revealed a similar result with the addition of LA (either LA alone or NO + LA), containing 63.6% of the variance between samples, conﬁrming that LA was also
the dominant component effecting protein alteration (Fig. 5C, bottom
panel). PC2 of total protein expression, with 21.3% of variance, was
also between (NO + LA) and all other treatment groups. Similarly, hierarchical cluster analysis (Fig. 5D) revealed that with both S-nitrosylation
and total protein differences, LA and (NO + LA) were clustered together,
and were separated from control and NO. Again, this suggests that
the addition of LA was the dominant factor regulating protein Snitrosylation.
Next, seven nitrosylated proteins and six proteins displaying significant changes in expression levels between the NO + LA and the NO
groups were identiﬁed by MS (Table 1 and Table 2). Among the seven
nitrosylated proteins, six proteins treated with (NO + LA) showed
decreased S-nitrosylation and one protein showed increased Snitrosylation levels at least two-fold above that of NO alone. Interestingly, supplementation of NO-treated cells with LA decreased the
nitrosylation of subunit I in complex III by 2.3-fold, and increased its
expression by 2.0-fold. In addition, LA decreased nitrosylation of
dihydrolipoyllysine succinyltransferase by 2.0-fold, a key component of
the enzyme KDC.

against HSP60, a mitochondrial matric protein, and β-tubulin, a cytosolic
protein. The results show that distribution of β-tubulin was not able to
be visualized in the mitochondrial fractions whereas intensity of
HSP60 exhibited a marked increase in mitochondrial fractions Fig. 6A
and 6B. The data clearly indicated a good enrichment of mitochondria
following the puriﬁcation. Complex III and KDC activities in the cells
treated with the NO donor dropped 25% and 37%, respectively, whereas
LA signiﬁcantly, restored partially both enzymatic activities (p b 0.05)
(Fig. 6C and D). To determine whether the alteration of these enzymes'
activities could be attributed to S-nitrosylation, we added the mitochondrial isolation buffer (pH 7.4) containing CuCl2 (10 μM) and ascorbic acid
(0.1 mM) to isolated mitochondria, followed by incubation at room temperature for 30 min. It is well known that Cu+ is a nitrosylating agent
[35,36]. Ascorbic acid was added to reduce Cu++ to Cu+ and prevent
Cu+ spontaneously oxidizing to Cu++. As Fig. 6E and F shows, both
enzyme activities were augmented after adding Cu+ to the NO-treated
group. We also found that in the presence of the speciﬁc Cu+ chelator
neocuproine (NCP, 100 μM) the effect of Cu+ was completely abolished.
However, adding the Cu++ chelator cuprizone (bis-cyclohexanoneoxalyldihydrazone, CPZ, 100 μM), had no effect (Fig. 6E and 6F). These
data show that the enzyme activities are affected by S-nitrosylation,
likely through a Cu+-dependent mechanism. By comparing the activity
values brought down by adding the NO donor and raised up by adding
Cu+, we conclude that S-nitrosylation has a major impact in the decline
of the enzymatic activities.

3.2. Complex III and KDC activities
4. Discussion
We found that complex III and KDC, which are primary energy
transducting mitochondrial enzymes, are nitrosylated, and that the
nitrosylation levels are reduced by adding LA. In order to further evaluate the impact of S-nitrosylation by NO and blocking of nitrosylation by
LA on the activities of complex III and KDC, we measured their enzymatic
activities in mitochondria isolated from aortic endothelial cells. The
purity of mitochondrial factions was assessed by Western blot analysis
and then quantitated by the Image software after normalization mitochondrial protein concentration to cytosol protein concentration. Mitochondrial and cytosolic fractions were immunoblotted with antibodies

In this study, we have demonstrated that a subunit of complex III in
the electron transport chain, and dihydrolipoyllysine succinyltransferase,
a subunit of KDC in the Krebs cycle, are susceptible to S-nitrosylation in
response to NO treatment. In addition, S-nitrosylation of complex III
and KDC coincide with a signiﬁcant decrease in the activities of these
two enzymes. These data demonstrate that S-nitrosylation decreases
enzyme activities. Although canonical NO signaling occurs likely through
its interaction with soluble guanylyl cyclase and controls cyclic guanosine monophosphate (cGMP)-dependent signaling, some investigations
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have suggested that protein S-nitrosation is an essential component
of vascular (dys)function [6]. The endothelium is an ideal site for Snitrosylation-dependent signals because endothelial cells constitutively
express the NO-producing enzyme endothelial nitric oxide synthase
(eNOS), and under inﬂammatory conditions, it is also exposed to nitric
oxide-derived from the inducible NOS isoform (iNOS) [14]. Our ﬁndings
support these observations. Importantly, our results reveal that LA
supplementation signiﬁcantly reduces S-nitrosylation on KDC and
complex III, and partially restores their activities as well. These results
disclose that regulation of protein S-nitrosylation is a novel redox regulatory mechanism of LA by which LA quenches NS to retain normal energy
homeostasis. Our results agree with observations by other investigators.
For instance, Murphy et al. found that KDC could be nitrosylated and that
the nitrosylated form of the enzyme becomes inactive [9]. On the other
hand, the fact that LA cannot completely abolish elevated levels of NO
and fully restore the enzyme activity suggest that besides protein
S-nitrosylation, other forms of regulations may exist. For example,
cGMP dependent signal pathway and peroxynitrite could be part of
these alternative mechanisms. It is well established that some biological
activities including regulation of mitochondrial biogenesis [37] by NO
are mediated via its primary receptor, the soluble guanylyl cyclase
(sGC) [38]. In addition, NO reacts readily with superoxide to produce
peroxynitrite, which can inhibit mitochondrial functions. Furthermore,
our data show that the impairment of OCAR/ECAR and the mitochondrial
reserve capacity after Deta-NONOate administration were readily
reversible upon the addition of LA. These observations suggest that this
rapid reversible reaction is not likely due to protein S-nitrosylation,
since covalent modiﬁcations are not usually reversible. Since free NO
can be converted into SNO and SNO can convert to NO, our current data
do not support any effect over the other; i.e., which effect is mediated
through free NO released from the NO donor or through S-nitrosylation
modiﬁcation.
We propose that diminished activities of complex III and KDC may
lead to the decreased ATP production observed in our experiments for
the following reasons: 1) complex III is a critical component of all
primary energy transduction systems. It functions in maintaining the
proton gradient, which provides ~30% of body energy [39]. 2) KDC is a
critical regulatory enzyme in the Krebs cycle [40], limiting the NADH
production rate and oxidative phosphorylation [41]. It is thought that
KDC plays a key role in bioenergetic deﬁcit associated with oxidative
stress [42]. 3) It is well-established that NO interacts with the mitochondrial respiratory chain by inhibiting cytochrome c oxidase (complex IV)
and NADH-ubiquinone oxidoreductase (complex I) [43,44]. And
4) mitochondrial proteins are constantly exposed to excess ROS [45];
therefore, are susceptible to oxidative damage, leading to energy
deﬁciency [46]. Inhibition of mitochondrial complexes in the electron
transport chain by excess NO leads to enhanced production of ROS
[47]. Our data revealed that levels of 4-HNE—a biomarker of lipid peroxidation [48], carbonylated proteins—a biomarker of protein oxidation
[49], and nitric oxide, were signiﬁcantly increased whereas GSH levels
were signiﬁcantly decreased in the mitochondrial fractions. 4-HNE is
derived from peroxidation of n-6 polyunsaturated fatty acids such as
arachidonic and linoleic acids and it is one of the most abundant and
active lipid peroxides. 4-HNE reacts with amino acids, such as cysteine,
lysine or histidine, and forms stable adducts with proteins, leading to
modulating activities of proteins. Carbonyl groups (aldehydes and
ketones) are produced on protein side chains (especially of Pro, Arg,
Lys, and Thr) where they are oxidized and increased. These alterations
are partially restored by LA supplementation. The data suggest that LA
may provide mitochondrial protection against NO damage, likely
through regulation of GSH, a predominantly intra-mitochondrial antioxidant that protects mitochondrial complexes from NO-induced damage
[50].
Our proteomics experiments indicate that most of the nitrosylated
proteins affected by LA supplementation are involved in protein folding
like protein disulﬁde-isomerase (PDI) and heat shock cognate 71 kDa

(Hsc70). LA treatment affected the nitrosylation levels of PDI and
Hsc70 by 4.6-fold increase and 3.0-fold decrease, respectively. PDI contains two thioredoxin domains that catalyze the formation, breakage,
and rearrangement of disulﬁde bonds [51]. Hsc70 is involved in
chaperoning unfolded proteins for degradation by both the ubiquitinproteasome system and liposomes [52]. We do not know whether
these observations could provide more evidences to support McCarty's
hypothesis. He postulated that LA could induce a heat shock response
by assisting the formation of intra-molecular disulﬁde bonds in signaling
proteins [53].
We have shown here that the expression of structural proteins
including zyxin, prohibitin, vimentin, lamin A/C and actin is affected
by excess NO, and changed by LA supplementation. We also observed
that in response to excess NO, nitrosylation of actin and vimentin
increased and appeared to decrease by LA supplementation. Zyxin is a
protein attached to the cytoskeleton helping to organize function,
dynamics and maintenance of actin ﬁbers [54]. In endothelial cells,
zyxin is activated in response to stretch, followed by translocation
from the cytoskeleton to the nucleus [55]. Prohibitin (PHB) acts as a
mediator of mitochondria shuttling in response to oxidative stress
[56]. PHB also acts as a molecular chaperone stabilizing newly synthesized respiratory enzymes in mitochondria [57]. It seems clear that LA
exerts multiple regulatory effects beyond direct ROS quenching. These
regulatory functions may involve altering protein S-nitrosylation and
regulation of the expression levels of some proteins that may be affected
by S-nitrosative mechanisms. Our ﬁndings also show that mitochondrial
proteins, regardless of their cytosolic or mitochondrial origin, and
cytosolic proteins such as zyxin and Hsc70, undergo S-nitrosylation in
the presence of elevated NO.
In summary, LA supplementation effectively restores mitochondrial
enzyme activities of complex III and the α-ketoglutarate dehydrogenase
complex inhibited by excess NO, mainly via S-nitrosylation. Regulation
of these two enzymes, particularly via reducing S-nitrosylation contributes to the protective effect observed. Our studies shed light on a new
mechanism of antioxidant activity of LA, and suggest a strategy for the
treatment of diseases in which chronic inﬂammation is involved.
Acknowledgments
The authors thank Dr. Rosaline Coleman for insightful suggestions
and Dr. Carol Parker for critically reviewing the manuscript. This
manuscript has been reviewed by the US Environmental Protection
Agency, NHEERL and approved for publication. The authors would like
to thank Drs. P.R. Kodavanti and J. Royland for their constructive comments. Approval does not signify that the contents reﬂect the views of
the US EPA, nor does mention of trade names or commercial products
constitute endorsement or recommendation for use.
This work was supported by the American Heart Association grant
#13GRNT17120056 (to X. Y.).
References
[1] R.M. Palmer, A.G. Ferrige, S. Moncada, Nitric oxide release accounts for the biological
activity of endothelium-derived relaxing factor, Nature 327 (1987) 524–526.
[2] R.M. Palmer, L. Bridge, N.A. Foxwell, S. Moncada, The role of nitric oxide in endothelial
cell damage and its inhibition by glucocorticoids, Br. J. Pharmacol. 105 (1992) 11–12.
[3] N.M. Iovine, S. Pursnani, A. Voldman, G. Wasserman, M.J. Blaser, et al., Reactive
nitrogen species contribute to innate host defense against Campylobacter jejuni, Infect. Immun. 76 (2008) 986–993.
[4] D. Behr-Roussel, A. Rupin, S. Simonet, E. Bonhomme, S. Coumailleau, et al., Effect of
chronic treatment with the inducible nitric oxide synthase inhibitor N-iminoethyl-Llysine or with L-arginine on progression of coronary and aortic atherosclerosis in
hypercholesterolemic rabbits, Circulation 102 (2000) 1033–1038.
[5] K.M. Cromheeke, M.M. Kockx, G.R. De Meyer, J.M. Bosmans, H. Bult, et al., Inducible
nitric oxide synthase colocalizes with signs of lipid oxidation/peroxidation in
human atherosclerotic plaques, Cardiovasc. Res. 43 (1999) 744–754.
[6] D.T. Hess, A. Matsumoto, S.O. Kim, H.E. Marshall, J.S. Stamler, Protein S-nitrosylation:
purview and parameters, Nat. Rev. Mol. Cell Biol. 6 (2005) 150–166.
[7] S. Moncada, Nitric oxide and cell respiration: physiology and pathology, Verh. K.
Acad. Geneeskd. Belg. 62 (2000) 171–179 (discussion 179-181).

S. Hiller et al. / Biochimica et Biophysica Acta 1860 (2016) 36–45
[8] B. Lima, M.T. Forrester, D.T. Hess, J.S. Stamler, S-nitrosylation in cardiovascular
signaling, Circ. Res. 106 (2010) 633–646.
[9] J. Sun, E. Murphy, Protein S-nitrosylation and cardioprotection, Circ. Res. 106 (2010)
285–296.
[10] P. Luedike, U.B. Hendgen-Cotta, J. Sobierajski, M. Totzeck, M. Reeh, et al.,
Cardioprotection through S-nitros(yl)ation of macrophage migration inhibitory
factor, Circulation 125 (2012) 1880–1889.
[11] A.R. Diers, K.A. Broniowska, N. Hogg, Nitrosative stress and redox-cycling agents
synergize to cause mitochondrial dysfunction and cell death in endothelial cells,
Redox Biol. 1 (2013) 1–7.
[12] D.B. Cines, E.S. Pollak, C.A. Buck, J. Loscalzo, G.A. Zimmerman, et al., Endothelial cells
in physiology and in the pathophysiology of vascular disorders, Blood 91 (1998)
3527–3561.
[13] F. Jiang, G.R. Drummond, G.J. Dusting, Suppression of oxidative stress in the
endothelium and vascular wall, Endothelium 11 (2004) 79–88.
[14] O.W. Grifﬁth, D.J. Stuehr, Nitric oxide synthases: properties and catalytic mechanism, Annu. Rev. Physiol. 57 (1995) 707–736.
[15] H.E. Marshall, J.S. Stamler, Nitrosative stress-induced apoptosis through inhibition of
NF-kappa B, J. Biol. Chem. 277 (2002) 34223–34228.
[16] J. Qian, D.J. Fulton, Exogenous, but not endogenous nitric oxide inhibits adhesion
molecule expression in human endothelial cells, Front. Physiol. 3 (2012) 3.
[17] L. Packer, E.H. Witt, H.J. Tritschler, Alpha-lipoic acid as a biological antioxidant, Free
Radic. Biol. Med. 19 (1995) 227–250.
[18] L.J. Reed, From lipoic acid to multi-enzyme complexes, Protein Sci. 7 (1998)
220–224.
[19] O. Tirosh, S. Shilo, A. Aronis, C.K. Sen, Redox regulation of mitochondrial permeability
transition: effects of uncoupler, lipoic acid and its positively charged analog LA-plus
and selenium, Biofactors 17 (2003) 297–306.
[20] X. Yi, N. Maeda, Endogenous production of lipoic acid is essential for mouse development, Mol. Cell. Biol. 25 (2005) 8387–8392.
[21] Hiller S, DeKroon R, Xu L, Robinette J, Winnik W, et al. Alpha-Lipoic acid protects
mitochondrial enzymes and attenuates lipopolysaccharide-induced hypothermia
in mice. Free Radic. Biol. Med. 71: 362–367.
[22] A.R. Diers, K.A. Broniowska, V.M. Darley-Usmar, N. Hogg, Differential regulation of
metabolism by nitric oxide and S-nitrosothiols in endothelial cells, Am. J. Physiol.
Heart Circ. Physiol. 301 (2011) H803–H812.
[23] W.J. Zhang, H. Wei, T. Hagen, B. Frei, Alpha-lipoic acid attenuates LPS-induced
inﬂammatory responses by activating the phosphoinositide 3-kinase/Akt signaling
pathway, Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 4077–4082.
[24] K.P. Shay, A.J. Michels, W. Li, A.N. Kong, T.M. Hagen, Cap-independent Nrf2 translation is part of a lipoic acid-stimulated detoxiﬁcation stress response, Biochim.
Biophys. Acta 1823 (2012) 1102–1109.
[25] J.R. Smith, H.V. Thiagaraj, B. Seaver, K.K. Parker, Differential activity of lipoic acid
enantiomers in cell culture, J. Herb. Pharmacother. 5 (2005) 43–54.
[26] B.P. Dranka, B.G. Hill, V.M. Darley-Usmar, Mitochondrial reserve capacity in
endothelial cells: the impact of nitric oxide and reactive oxygen species, Free
Radic. Biol. Med. 48 (2010) 905–914.
[27] D.A. Clayton, G.S. Shadel, Isolation of mitochondria from cells and tissues, Cold
Spring Harb. Protoc. 10 (2014) 1109–1111.
[28] M.R. Wieckowski, C. Giorgi, M. Lebiedzinska, J. Duszynski, P. Pinton, Isolation of
mitochondria-associated membranes and mitochondria from animal tissues and
cells, Nat. Protoc. 4 (2009) 1582–1590.
[29] S.R. Jaffrey, S.H. Snyder, The biotin switch method for the detection of S-nitrosylated
proteins, Sci. STKE 2001 (2001) l1.
[30] R.M. DeKroon, J.B. Robinette, C. Osorio, J.S. Jeong, E. Hamlett, et al., Analysis of
protein posttranslational modiﬁcations using DIGE-based proteomics, Methods
Mol. Biol. 854 (2012) 129–143.
[31] R.M. DeKroon, C. Osorio, J.B. Robinette, M. Mocanu, W.M. Winnik, et al., Simultaneous detection of changes in protein expression and oxidative modiﬁcation as a
function of age and APOE genotype, J. Proteome Res. 10 (2011) 1632–1644.
[32] W.M. Winnik, R.M. Dekroon, J.S. Jeong, M. Mocanu, J.B. Robinette, et al., Analysis of
proteins using DIGE and MALDI mass spectrometry, Methods Mol. Biol. 854
(2012) 47–66.

45

[33] A.C. Nulton-Persson, L.I. Szweda, Modulation of mitochondrial function by hydrogen
peroxide, J. Biol. Chem. 276 (2001) 23357–23361.
[34] I.A. Trounce, Y.L. Kim, A.S. Jun, D.C. Wallace, Assessment of mitochondrial oxidative
phosphorylation in patient muscle biopsies, lymphoblasts, and transmitochondrial
cell lines, Methods Enzymol. 264 (1996) 484–509.
[35] H.H. Al-Sa'doni, I.L. Megson, S. Bisland, A.R. Butler, F.W. Flitney, Neocuproine, a
selective Cu(I) chelator, and the relaxation of rat vascular smooth muscle by
S-nitrosothiols, Br. J. Pharmacol. 121 (1997) 1047–1050.
[36] R.J. Singh, N. Hogg, J. Joseph, B. Kalyanaraman, Mechanism of nitric oxide release
from S-nitrosothiols, J. Biol. Chem. 271 (1996) 18596–18603.
[37] E. Nisoli, E. Clementi, C. Paolucci, V. Cozzi, C. Tonello, et al., Mitochondrial biogenesis
in mammals: the role of endogenous nitric oxide, Science 299 (2003) 896–899.
[38] Wobst J, Kessler T, Dang TA, Erdmann J, Schunkert H. Role of sGC-dependent NO
signalling and myocardial infarction risk. J. Mol. Med. 93: 383–394.
[39] A.R. Crofts, The cytochrome bc1 complex: function in the context of structure, Annu.
Rev. Physiol. 66 (2004) 689–733.
[40] G.J. Cooney, H. Taegtmeyer, E.A. Newsholme, Tricarboxylic acid cycle ﬂux and
enzyme activities in the isolated working rat heart, Biochem. J. 200 (1981) 701–703.
[41] L. Tretter, V. Adam-Vizi, Inhibition of Krebs cycle enzymes by hydrogen peroxide: a
key role of [alpha]-ketoglutarate dehydrogenase in limiting NADH production under
oxidative stress, J. Neurosci. 20 (2000) 8972–8979.
[42] L. Tretter, V. Adam-Vizi, Alpha-ketoglutarate dehydrogenase: a target and generator
of oxidative stress, Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci. 360 (2005) 2335–2345.
[43] M. Huttemann, I. Lee, A. Pecinova, P. Pecina, K. Przyklenk, et al., Regulation of oxidative phosphorylation, the mitochondrial membrane potential, and their role in
human disease, J. Bioenerg. Biomembr. 40 (2008) 445–456.
[44] J. Zhang, B. Jin, L. Li, E.R. Block, J.M. Patel, Nitric oxide-induced persistent inhibition
and nitrosylation of active site cysteine residues of mitochondrial cytochrome-c
oxidase in lung endothelial cells, Am. J. Physiol. Cell Physiol. 288 (2005) C840–C849.
[45] E. Barreiro, A.S. Comtois, J. Gea, V.E. Laubach, S.N. Hussain, Protein tyrosine nitration
in the ventilatory muscles: role of nitric oxide synthases, Am. J. Respir. Cell Mol. Biol.
26 (2002) 438–446.
[46] N.R. Madamanchi, M.S. Runge, Mitochondrial dysfunction in atherosclerosis, Circ.
Res. 100 (2007) 460–473.
[47] A. Musatov, N.C. Robinson, Susceptibility of mitochondrial electron-transport
complexes to oxidative damage. Focus on cytochrome c oxidase, Free Radic. Res.
46 (2012) 1313–1326.
[48] X. Zhang, Z. Wang, J. Li, D. Gu, S. Li, et al., Increased 4-hydroxynonenal formation
contributes to obesity-related lipolytic activation in adipocytes, PLoS One 8
(2013), e70663.
[49] I. Dalle-Donne, R. Rossi, D. Giustarini, A. Milzani, R. Colombo, Protein carbonyl
groups as biomarkers of oxidative stress, Clin. Chim. Acta 329 (2003) 23–38.
[50] D. Brealey, M. Singer, Mitochondrial dysfunction in sepsis, Curr. Infect. Dis. Rep. 5
(2003) 365–371.
[51] T. Pihlajaniemi, T. Helaakoski, K. Tasanen, R. Myllyla, M.L. Huhtala, et al., Molecular
cloning of the beta-subunit of human prolyl 4-hydroxylase. This subunit and protein
disulphide isomerase are products of the same gene, EMBO J. 6 (1987) 643–649.
[52] E. Meimaridou, S.B. Gooljar, N. Ramnarace, L. Anthonypillai, A.J. Clark, et al., The
cytosolic chaperone Hsc70 promotes trafﬁc to the cell surface of intracellular
retained melanocortin-4 receptor mutants, Mol. Endocrinol. 25 (2011) 1650–1660.
[53] M.F. McCarty, Versatile cytoprotective activity of lipoic acid may reﬂect its ability to
activate signalling intermediates that trigger the heat-shock and phase II responses,
Med. Hypotheses 57 (2001) 313–317.
[54] T. Macalma, J. Otte, M.E. Hensler, S.M. Bockholt, H.A. Louis, et al., Molecular characterization of human zyxin, J. Biol. Chem. 271 (1996) 31470–31478.
[55] S. Suresh Babu, A. Wojtowicz, M. Freichel, L. Birnbaumer, M. Hecker, et al., Mechanism of stretch-induced activation of the mechanotransducer zyxin in vascular
cells, Sci. Signal. 5 (2012) ra91.
[56] H. Lee, H. Arnouk, S. Sripathi, P. Chen, R. Zhang, et al., Prohibitin as an oxidative
stress biomarker in the eye, Int. J. Biol. Macromol. 47 (2010) 685–690.
[57] L.G. Nijtmans, L. de Jong, M. Artal Sanz, P.J. Coates, J.A. Berden, et al., Prohibitins act
as a membrane-bound chaperone for the stabilization of mitochondrial proteins,
EMBO J. 19 (2000) 2444–2451.

